Top Markets
Coin of the day
Scilex Holding Company Scilex Holding Company

Scilex Holding Company

SCLX
주식 순위 #25633
Scilex Holding Company is a biopharmaceutical enterprise that specializes in... Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.
주가
$5.61
마지막 동기화: 2026-08-20
시가총액
$47.65M
변동 (1일)
-0.68%
변동 (1년)
-67.26%
국가
US
거래 Scilex Holding Company (SCLX)

카테고리

Scilex Holding Company (SCLX)의 P/B 비율
2026 기준 P/B 비율 TTM: 0
Scilex Holding Company의 최신 재무 보고서와 주가에 따르면 현재 P/B 비율(TTM)은 0입니다. 2026년 말 기준 P/B 비율은 0였습니다.
Scilex Holding Company의 P/B 비율 기록 (2026 ~ 2026)
매년 말 P/B 비율
연도 P/B 비율 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 P/B 비율
회사 P/B 비율 P/B 비율 차이 국가
31.0864 -
US
7.4766 -
US
-74.4354 -
US
8.4776 -
CH
8.008 -
US